** Shares of biotech company Renovaro Inc up 24.4% at $0.87
** David Weinstein appointed as RENB's director and CEO, succeeding Mark Dybul
** Co also names four new directors; board size increased to five members
** Realignment of resources to focus on RENB's AI platform, Renovaro Cube, which is used for multi-cancer early detection and patient monitoring
** Strategic review to also include pipeline prioritization and financial initiatives to strengthen co's balance sheet
** Up to last close, stock down ~73.35% YTD
(Reporting by Rishab Shaju in Bengaluru)
((Rishab.shaju@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.